Compare THRY & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | PEPG |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 121.7M |
| IPO Year | 2020 | 2022 |
| Metric | THRY | PEPG |
|---|---|---|
| Price | $3.92 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $9.33 | ★ $11.17 |
| AVG Volume (30 Days) | ★ 1.0M | 836.8K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | 25.61 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $1.01 |
| 52 Week High | $14.28 | $7.80 |
| Indicator | THRY | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 35.98 |
| Support Level | $3.14 | $1.32 |
| Resistance Level | $4.17 | $5.37 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 68.34 | 27.78 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.